Advertisement

Advertisement

AQST Stock Latest News

Aquestive Shareholders Back Directors, Pay Plan, Auditor

Company AnnouncementsAquestive Shareholders Back Directors, Pay Plan, Auditor

Aquestive Therapeutics Charts Cautious, Liquid Path Forward

PremiumCompany Announcements

Aquestive Therapeutics Charts Cautious, Liquid Path Forward

1M ago

Aquestive Therapeutics Signals Momentum In Earnings Call

PremiumCompany Announcements

Aquestive Therapeutics Signals Momentum In Earnings Call

1M ago

Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips

PremiumThe Fly

Midday Fly By: Cisco reports Q3 beat, Chinese firms cleared to buy Nvidia chips

1M ago

Aquestive Secures New Oaktree Term Loan to Fund Anaphylm

PremiumCompany Announcements

Aquestive Secures New Oaktree Term Loan to Fund Anaphylm

1M ago

Aquestive Therapeutics reports Q1 EPS (7c), consensus (13c)

PremiumThe FlyAquestive Therapeutics reports Q1 EPS (7c), consensus (13c)

1M ago

Aquestive Therapeutics options imply 7.1% move in share price post-earnings

The Fly

Aquestive Therapeutics options imply 7.1% move in share price post-earnings

1M ago

AQST Upcoming Earnings Report: What to Expect?

Pre-Earnings

AQST Upcoming Earnings Report: What to Expect?

1M ago

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

PremiumThe Fly

Aquestive Therapeutics assumed with an Outperform at Oppenheimer

2M ago

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

PremiumMarket News

Investor Sue Aquestive Therapeutics Over ‘Postage Stamp’ Anaphylaxis Treatment Claims

2M ago

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline

PremiumClass Action

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged Misleading Statements About Anaphylm FDA Approval Timeline

3M ago

Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting

PremiumCompany Announcements

Aquestive Advances Anaphylm NDA Resubmission After FDA Meeting

3M ago

Aquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

PremiumThe FlyAquestive Therapeutics completes Type A meeting with FDA for Anaphylm NDA

3M ago

Aquestive Therapeutics Announces Key Legal Leadership Transition

Company Announcements

Aquestive Therapeutics Announces Key Legal Leadership Transition

3M ago

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

The Fly

Aquestive chief legal officer, chief compliance officer Lori Braender steps down

3M ago

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm

PremiumClass Action

Aquestive Therapeutics Faces Investor Lawsuit Over Alleged FDA Approval Misrepresentations for Anaphylm

3M ago

Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target

PremiumRatings

Reiterating Buy on Aquestive: Near-Term Cost Pressures Offset by Anaphylm-Driven 2027 Growth Potential and $10 Target

3M ago

Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch

PremiumCompany Announcements

Aquestive Therapeutics Maps Risky Path to ANNAFILM Launch

3M ago

AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability

PremiumCompany Announcements

AI Execution Risks Threaten Aquestive Therapeutics’ Competitiveness and Profitability

4M ago

Aquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

PremiumThe FlyAquestive Therapeutics price target lowered to $9 from $12 at Alliance Global

4M ago

Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook

Company Announcements

Aquestive Therapeutics Amends RTW Deal, Strengthens Financing Outlook

4M ago

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

The Fly

Aquestive Therapeutics reports Q4 adjusted EPS (15c), consensus (12c)

4M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >